



dottikon

MEDIA RELEASE

Dottikon, January 17, 2012

DOTTIKON ES – Nomination for Election of Dr. Thomas Früh to the Board of Directors

Dottikon, Switzerland, January 17, 2012 – The Board of Directors nominates Dr. Thomas Früh to be newly elected to the Board of Directors of DOTTIKON ES HOLDING AG at the next Annual General Meeting of July 6, 2012, to assure the orderly transition when the two members of the Board of Directors Heinz Boller and Dr. h.c. Peter Grogg will no longer put themselves forward for reelection for reasons of age. Dr. Thomas Früh is COO of Bachem AG, Switzerland, and designated CEO of Bachem Group.

DOTTIKON ES, with its production site in Dottikon (Aargau, Switzerland), is specialized in hazardous chemical reactions. Its safety culture created over the last 100 years is utilized to innovatively use hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing, to question, tighten or shorten conventional chemical synthesis routes, improve yields, selectivity, and purity, as well as to reduce waste.

DOTTIKON ES employs its versatile technology and equipment portfolio to design, develop, and continuously improve chemical processes, scale up from kilograms to multi-tons, as well as to manufacture high-quality intermediates and exclusive active pharmaceutical ingredients (APIs) for the world's leading pharmaceutical and chemical companies. The one-site strategy of DOTTIKON ES allows short decision and communication pathways. This ensures quick and efficient project development as well as clear and transparent communication with the customers.

DOTTIKON ES HOLDING AG is listed at the SIX Swiss Exchange.

Symbol: DESN

Security number: 2073900

ISIN: CH0020739006

For further information please contact

Markus Blocher, Ph.D.
CEO

Dottikon ES Holding AG
Tel +41 56 616 82 01
Fax +41 56 616 89 45
investor-relations@dottikon.com